Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy, is a technique of external beam radiation that delivers precisely targeted, ablative doses to extracranial sites. It has become an integral component of the management of early-stage non–small cell lung cancer (NSCLC). In this review, we discuss the technology and techniques used in treatment planning and delivery, the efficacy and toxicity of SBRT for medically inoperable early-stage NSCLC, and the preliminary investigations into the role of SBRT for operable early-stage NSCLC.
From the Radiation Oncology Department, University of Texas Southwestern Medical Center, Dallas, TX.
Conflicts of Interest and Source of Funding: R.T. discloses funding from the US National Institutes of Health, a government organization, which funded the early trials in lung stereotactic body radiation therapy performed at Indiana University, as well as the Radiation Therapy Oncology Group studies. G.M. has disclosed that she has no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Reprints: Robert Timmerman, MD, University of Texas Southwestern Medical Center, Moncrief Radiation Oncology Bldg, 5801 Forest Park Rd, 2nd Floor, Dallas, TX 75390. E-mail: Robert.Timmerman@utsouthwestern.edu.